SenesTech Faces Delisting Concerns

TL;DR

SNES might get kicked off the exchange - big trouble.

AI Summary

SenesTech, Inc. filed an 8-K on July 31, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company, incorporated in Delaware, is based in Flagstaff, Arizona, and operates in the agriculture chemicals sector.

Why It Matters

This filing indicates potential issues with SenesTech's compliance with stock exchange listing requirements, which could lead to the company's shares being delisted.

Risk Assessment

Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.

Key Players & Entities

• SenesTech, Inc. (company) — Registrant
• July 31, 2024 (date) — Date of earliest event reported
• Flagstaff, Arizona (location) — Company headquarters
• Delaware (location) — State of incorporation

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value SNES The Nasdaq Stock Market

Filing Documents

• snes-20240731.htm (8-K) — 26KB
• 0001628280-24-034717.txt ( ) — 150KB
• snes-20240731.xsd (EX-101.SCH) — 2KB
• snes-20240731_lab.xml (EX-101.LAB) — 22KB
• snes-20240731_pre.xml (EX-101.PRE) — 13KB
• snes-20240731_htm.xml (XML) — 3KB

01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Delphine Franois Chiavarini's position as a member of our board of directors (the "Board") expired at our 2024 annual meeting of stockholders. Ms. Franois Chiavarini also served as a member of our audit committee (the "Audit Committee"). On July 31, 2024, we received a letter from the listing qualifications staff (the "Staff") of The Nasdaq Stock Market ("Nasdaq") providing notification that due to the departure of Ms. Franois Chiavarini from our Board and Audit Committee effective July 11, 2024, we no longer comply with Nasdaq's audit committee requirements as set forth in Nasdaq Listing Rule 5605 (the "Rule"). The Rule requires, among other things, that the Audit Committee be comprised of at least three independent directors. In accordance with Nasdaq Listing Rule 5605(c)(4), Nasdaq will provide us a cure period in order to regain compliance as follows (i) until the earlier of our next annual stockholders' meeting or July 11, 2025; or (ii) if the next annual stockholders' meeting is held before January 7, 2025, then we must evidence compliance no later than January 7, 2025. In the event we do not regain compliance prior to the expiration of the applicable cure period, the Nasdaq Listing Rules require the Staff to provide written notification to us that our securities will be delisted. At that time, we may appeal the Staff's determination to a Nasdaq hearings panel. The Nasdaq notification has no immediate effect on the listing of our common stock on the Nasdaq Capital Market. We intend to rely on the cure period to reestablish compliance with the Rule. We are in the process of identifying and selecting a Board member who qualifies as independent and meets the audit committee criteria set forth in the Rule prior to the expiration of the cure period. However, there can be no assurance that we will regain compliance with the Rule or maintain complian

View Full Filing

View this 8-K filing on SEC EDGAR